BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Express Scripts
Harvard Business School
Fish and Richardson
Fuji
Argus Health
Medtronic
Chinese Patent Office
Covington
Farmers Insurance

Generated: January 18, 2018

DrugPatentWatch Database Preview

MEGACE ES Drug Profile

« Back to Dashboard

Which patents cover Megace Es, and when can generic versions of Megace Es launch?

Megace Es is a drug marketed by Endo Pharms Inc and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in twenty-eight countries.

The generic ingredient in MEGACE ES is megestrol acetate. There are eighteen drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.
Summary for MEGACE ES
Drug patent expirations by year for MEGACE ES
Pharmacology for MEGACE ES
Ingredient-typeProgesterone Congeners
Drug ClassProgestin
Medical Subject Heading (MeSH) Categories for MEGACE ES

US Patents and Regulatory Information for MEGACE ES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MEGACE ES
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Oral Suspension 125 mg/mL ➤ Subscribe

Non-Orange Book US Patents for MEGACE ES

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers ➤ Subscribe
7,459,283 Nanoparticulate compositions having lysozyme as a surface stabilizer ➤ Subscribe
8,236,352 Glipizide compositions ➤ Subscribe
6,316,029 Rapidly disintegrating solid oral dosage form ➤ Subscribe
8,323,641 Nanoparticulate compositions having lysozyme as a surface stabilizer ➤ Subscribe
8,293,277 Controlled-release nanoparticulate compositions ➤ Subscribe
7,276,249 Nanoparticulate fibrate formulations ➤ Subscribe
7,927,627 Nanoparticulate fibrate formulations ➤ Subscribe
7,850,995 Bioadhesive nanoparticulate compositions having cationic surface stabilizers ➤ Subscribe
7,521,068 Dry powder aerosols of nanoparticulate drugs ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for MEGACE ES

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Argus Health
Teva
Cantor Fitzgerald
Cipla
US Department of Justice
UBS
Boehringer Ingelheim
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot